A Phase 2 interventional study of Sotatercept in Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
What hematopoietic precursor compartments as well as hemoglobin subtypes are affected by dosing with sotatercept (ACE-011)? Based upon a similar prior study with Procrit, Celgene has determined that all of these goals could be obtained by an intense 10-patient sotatercept (ACE-011) pharmacodynamic study, completed by two well-known experts in the red cell production field.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
At the time of screening, participants who have any grade ≥3 toxicity (according to the currently active minor version of v4.0) except for the following disease-related toxicities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.
Drug: Sotatercept
single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
Also known as: ACE 011
Change From Baseline in Red Blood Cell Mass Following a Single Dose of Sotatercept
Blood samples were to be collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in red blood cell mass following a single dose of sotatercept.
Time frame: Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28
Change From Baseline in Plasma Volume Following a Single Dose of Sotatercept
Blood samples were collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in plasma volume following a single dose of sotatercept.
Time frame: Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28
Change From Baseline in Absolute Reticulocyte Count
Blood samples were to be collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in absolute reticulocyte count.
Time frame: Baseline (Day 1, pre-dose) and Day 211
Change From Baseline in Erythropoietin Levels
Blood samples were collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in erythropoietin levels.
Time frame: Baseline (Day 1, pre-dose) and Day 211
Change From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A following a single dose of sotatercept.
Time frame: Baseline (Day 1, pre-dose) and Day 29
Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.
Time frame: Baseline (Day 1, pre-dose) and Day 29
Change From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype C following a single dose of sotatercept.
Time frame: Baseline (Day 1, pre-dose) and Day 29
Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to approximately 7 months
| Milestone | Sotatercept |
|---|---|
| Started | 5 |
| Treated | 4 |
| Completed | 2 |
| Not completed | 3 |
| Withdrew: Death | 2 |
| Withdrew: Disease progression | 1 |
Blood samples were to be collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in red blood cell mass following a single dose of sotatercept.
No measurements were reported for this outcome.
Blood samples were collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in plasma volume following a single dose of sotatercept.
| mL | Sotatercept |
|---|---|
| Change From Baseline in Plasma Volume Following a Single Dose of Sotatercept | -239.50 ± 219.91 |
Blood samples were to be collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in absolute reticulocyte count.
No measurements were reported for this outcome.
Blood samples were collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in erythropoietin levels.
| IU/L | Sotatercept |
|---|---|
| Change From Baseline in Erythropoietin Levels | 11.30 (11.3 to 11.3) |
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A following a single dose of sotatercept.
| Percentage of hemoglobin subtype A | Sotatercept |
|---|---|
| Change From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept | 0.0 (0.0 to 0.0) |
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.
| Percentage of hemoglobin subtype A2 | Sotatercept |
|---|---|
| Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept | 0.0 (0.0 to 0.0) |
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype C following a single dose of sotatercept.
| Percentage of hemoglobin subtype C | Sotatercept |
|---|---|
| Change From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept | 0.0 (0.0 to 0.0) |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Sotatercept |
|---|---|
| Number of Participants Who Experienced One or More Adverse Events (AEs) | 4 |
Collected over Up to approximately 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotatercept 35 mg | 2/5 (40%) | 3/4 (75%) | 4/4 (100%) |
| Event | Sotatercept 35 mg |
|---|---|
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 1/4 |
| CARDIOGENIC SHOCKCardiac disorders | 1/4 |
| ABDOMINAL PAINGastrointestinal disorders | 1/4 |
| PNEUMOPERITONEUMGastrointestinal disorders | 1/4 |
| DEVICE DISLOCATIONGeneral disorders | 1/4 |
| INFECTED SKIN ULCERInfections and infestations | 1/4 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 1/4 |
| DEHYDRATIONMetabolism and nutrition disorders | 1/4 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 1/4 |
| Event | Sotatercept 35 mg |
|---|---|
| VOMITINGGastrointestinal disorders | 3/4 |
| OEDEMA PERIPHERALGeneral disorders | 2/4 |
| ANAEMIABlood and lymphatic system disorders | 1/4 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/4 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/4 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 1/4 |
| ASCITESGastrointestinal disorders | 1/4 |
| CONSTIPATIONGastrointestinal disorders | 1/4 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 1/4 |
| NAUSEAGastrointestinal disorders | 1/4 |
| Age, Continuous(Years) | Sotatercept |
|---|---|
| Mean | 63.8 ± 8.8 |
| Sex: Female, Male(Participants) | Sotatercept |
|---|---|
| Female | 3 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Sotatercept |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Sotatercept |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2010 to primary completion in Sep 2012, 27 months.
Results were first posted in Nov 2023, 11 years 2 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept